



The growing wealth of information regarding the influence that physicochemical characteristics play 2 
on nanoparticle biocompatibility and safety is allowing improved design and rationale for their 3 
development and pre-clinical assessment. Accurate and appropriate measurement of these 4 
characteristics accompanied by informed toxicological assessment is a necessity for the 5 
development of safe and effective nanomedicines. While particle type, formulation, and mode of 6 
administration dictate the individual causes for concern through development, the benefits of 7 
nanoformulation for treatment of the diseased state are great. Here we have proposed certain 8 
considerations and suggestions which could lead to better informed pre-clinical assessment of 9 
nanomaterials for nanomedicine, as well as how this information can and should be extrapolated to 10 
the physiological state of the end user.  11 
Key Words 12 
Nanoparticles, Nanotoxicology, Nanomedicine 13 
 14 
Introduction 15 
The application of nanotechnology in a healthcare setting offers many novel therapeutic strategies 16 
that may improve existing therapies and diagnostics. Desirable physicochemical characteristics (PCC) 17 
of nanoparticles that can translate to medical benefits include structural and stability related 18 
properties to improve bioavailability, biodistribution and reduce clearance [1, 2]. Additionally, there 19 
are opportunities for targeted therapies, which may reduce undesirable effects in other cell types, 20 
and co-formulation that may alleviate pill burden in diseases such as HIV as well as simplifying 21 
dosing strategies by enabling parenteral long-acting depot formulations.  22 
While there are obvious advantages to the application of nanotechnology, it is entirely possible that 23 
it will not be a case of “one size fits all” and that certain drugs may only be compatible with 24 
particular nanoparticles or nanoformulation strategies. Indeed, nanomedicine has attracted recent 25 
interest in the fields of precision- and personalised-medicine [3]. 26 
Size, charge, hydrophobicity and shape are some of the numerous characteristics that can be tuned 27 
by the manufacturing process. Modification of these properties can alter the biological interactions 28 
of these nanoparticles. For example, uptake of gold nanoparticles by epithelial cells has been shown 29 
to be size-dependent where the rate increases with decreasing nanoparticle size [4], and 30 
hydrophobic modification of glycol chitosan nanoparticles increased uptake in cancer cells [5]. 31 
The heterogeneity of nanoparticles being produced by various inventors is a major advantage as it 32 
provides many options for the treatment of a broad range of diseases by enabling many strategies 33 
for the formulation of therapeutic compounds as well as allowing interactions with many 34 
therapeutics. However, the broad spectrum of nanoparticle classes, in addition to their 35 
physicochemical characteristics, presents a challenge in determining their biocompatibility. A 36 
balance should be found between nanoparticle characteristics that favour the delivery of 37 
therapeutic agents while simultaneously not resulting in issues around either toxicity or undesirable 38 
interactions with the immune system. Clearly therefore, a rational understanding of how 39 
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nanoparticle physical properties relate to their biological interactions is required for the efficient 40 
development of beneficial materials. 41 
 42 
Interaction of nanoparticles with components of the immune system 43 
There are many well-described interactions of nanoparticles with cells of the immune system [6]. 44 
The reasons for these interactions may be linked to specific nanoparticle properties, in particular size 45 
and charge [7-9]. Many nanoparticles are within the size range of microorganisms that the immune 46 
system has evolved to recognise, with many signatures in common with invading pathogens [10]. 47 
The mechanism by which nanoparticles are internalised varies between immune cell types. As 48 
demonstrated in Figure 1 this includes, but is not limited to, phagocytosis, endocytosis, passive 49 
uptake, and receptor-interaction based uptake. Phagocytosis (a process performed by macrophages, 50 
monocytes, neutrophils, dendritic cells, and mast cells) leads to the capture and internalisation of 51 
nanoparticles in phagosomes which in turn undergo lysosomal degradation [11]. While this is an 52 
effective tool for removing biological pathogens, nanoparticles are not so simply degraded. The pH 53 
environment of the phagolysosome may affect the stability of the nanoparticle leading to the 54 
release of metallic ions in the case of metallic nanoparticles [12]. These in turn can disrupt 55 
mitochondrial processes and generate reactive oxygen species through Fenton type reactions [12]. A 56 
similar effect can be observed in clathrin-mediated [13] and clathrin-independent endocytosis [14] 57 
where degradation occurs following lysosomal fusion with the endosome. Caveolin-mediated 58 
endosomes bypass lysosomal degradation [15] the mechanism of which is being explored for its 59 
potential for intracellular delivery of nanomaterials [16]. 60 
Nanoparticles which passively enter the cell, or those which escape phagocytic/endocytic vesicles 61 
are then able to come in direct contact with intracellular proteins and organelles [17], with the 62 
potential to interact in a detrimental manner. Internalised nanoparticles have been shown to 63 
interfere with the normal autophagic process [18] and also as a result modulate the NLRP3 64 
inflammasome [19].  65 
Interaction with certain classes of cell surface receptors leads to the internalisation of nanoparticles, 66 
usually displaying certain surface motifs [20] although this is not a necessity as scavenger receptors 67 
have been shown to bind polystyrene via the action of macrophage receptor with collagenous 68 
structure (MARCO) [21]. Activation of receptor associated pathways as a result of the binding of 69 
nanoparticles has been demonstrated where TLR4 signal transduction following the binding of 70 
polyethylenimine-coated SPIONs [22]. 71 
In addition to size and charge, hydrophobicity has also been demonstrated to be an important factor 72 
in the recognition of nanoparticles by the immune system [23]. As many intracellular danger-73 
associated molecular patterns (DAMPs) are hydrophobic in nature their release upon cellular 74 
damage signals to the immune system to respond to this damage. Hydrophobic nanoparticles have 75 
been shown to more likely induce an immune response than those which are less hydrophobic [24]. 76 
As more classes/types of nanomaterials are created it is entirely possible that additional 77 
nanoparticle characteristics will be recognised for their association with biocompatibility, and 78 
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nanoparticles may be stratified for their interactions with the immune system by class-specific 79 
properties. 80 
81 
Figure 1 – Routes of entry determine nanoparticle intracellular effects, and extracellular 82 
consequences. Internalisation of nanomaterials includes, but is not limited to, endocytosis (including 83 
phagocytosis), receptor-binding, and passive uptake. The fate, and associated intracellular effects of 84 
these mechanisms include lysosomal degradation, generation of by-products such as metal ions 85 
which can induce reactive oxygen species generation in mitochondria, direct interference with 86 
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intracellular processes involved in autophagy and the NLRP3-inflammasome, and activation of 87 
intracellular cascades such as the scavenger receptor pathway, TLR4 cascade, MAPK pathway, and 88 
the lectin pathway. Extracellular consequences include exocytosis, cytokine secretion, and 89 
complement activation. Effects displayed here are non-exhaustive, some being ubiquitous and not 90 
limited to individual modes of entry to the cell. Acronyms used; R.O.S. - reactive oxygen species, 91 
NLRP3 - NLR family pyrin domain containing 3, TLR4 - Toll-like receptor 4, MAPK - mitogen activated 92 
protein kinase. 93 
 94 
Stimulation of the immune system by nanoparticles 95 
As foreign substances to the body, nanoparticles may be recognised by the immune system and 96 
removed with the possibility to stimulate immune responses by both innate and adaptive 97 
mechanisms. Immunogenicity of nanomaterials is largely reliant on their route of administration, as 98 
this greatly affects their presentation to the immune system [25].  99 
Intravenously administered nanomedicines come directly into contact with plasma proteins which, 100 
depending on; particle characteristics, composition and the method of preparation result in protein 101 
binding to the nanomaterial surface [26, 27]. While the formation of a “protein corona” is ubiquitous 102 
to all nanomaterials when subjected to a biological medium, it has been shown to have important 103 
implications for many aspects of nanoparticle-biological interactions in vivo [28] such as activating 104 
complement [29], and differential cellular uptake dependent on coronal composition [30]. Recent 105 
work by Tenzer et al. [31] has furthered the understanding of the temporal composition of the 106 
nanoparticle corona. While this work was unable to also investigate the “soft corona”, the presence 107 
of which further increases the complexity of nanoparticle presentation to the immune system, it has 108 
shown that the coronal structure changes as a function of time affecting the material’s 109 
pathophysiology. 110 
Currently, nanoparticle antigenicity is not well understood. The process of antigenicity involves 111 
plasma B cells to generate antibodies against the nanoparticle, or functional groups, such as 112 
peptides, attached to the particle surface [32]. Since nanoparticle specific antibodies should only 113 
influence the effectiveness of particle-based products, for example by modulating cellular 114 
interactions or biodistribution, it is more probable that antibodies that recognise the functional 115 
ligands present on the nanoparticle surface may cause similar clinical results as those seen for 116 
biotechnology-derived therapeutics [33, 34]. Anti-nanoparticle immunoglobulin formation has been 117 
reported. Polyclonal C60-specific antibodies with a subpopulation cross-reacting with the C70 118 
fullerene have been demonstrated, as well as monoclonal antibody responses to C60 fullerenes [35, 119 
36]. PEGylation (the functionalization of nanoparticles with polyethylene glycol chains) has been 120 
used to reduce their immunogenic potential, but the production of anti-PEG antibodies has also 121 
been reported [37, 38]. 122 
Examples of specific nanoparticle properties influencing immune stimulation have been reported. 123 
For instance, cationic nanoparticles have a greater potential to induce inflammatory responses than 124 
neutral or anionic nanomaterials. An example of this are positively charged 4.5 polyaminoamine 125 
(PAMAM) dendrimers do not cause the secretion of cytokines by human leukocytes [39] whereas 126 
negatively charged liposomes cause the production of interleukin-2 and interferon gamma [40]. CD4 127 
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expressing T lymphocytes, known as T helper cells (Th), are a key cell type for the secretion of 128 
cytokines. Th cells may be divided into TH1 and TH2, which produce Th1-type or Th2-type cytokines, 129 
respectively. Several studies have addressed the influence of nanoparticles on Th1 and Th2 130 
responses [41-43]. Th1 cells activate and support cell-mediated immunity, killing virally infected or 131 
malignant cells while Th2 cells induce humoral immunity and support antibody production by B cells. 132 
Large (>1 μm) industrialized particles induce Th1 responses, whereas smaller (<500 nm) particles are 133 
linked with Th2 response [44]. In contrast, engineered nanomaterials including 80 nm and 100 nm 134 
nanoemulsions [45, 46], 123 nm self-assembled dendrimers [47], 270 nm poly(lactic-co-glycolic) acid 135 
(PLGA) [48], and 500 nm PLGA [49] induce Th1 response. Other engineered particles (e.g. 5 nm 136 
generation-5 PAMAM dendrimers) do not demonstrate in vivo inflammatory reactions, but enhance 137 
immunoglobulin production and weakly induce Th2 cytokine production [50]. The potential 138 
contradiction in these findings warrants further investigation to establish whether this is due to 139 
nanoparticle characteristics or varying experimental approaches.   140 
Macrophages are able to phagocytose nanoparticles, the size of which influences the observed 141 
stimulatory effects most likely due to size dependent thresholds on the phagocytic capacity of 142 
macrophages [51]. Nanoparticles of the range 200-600nm induce IFNγ, favouring a Th1 type 143 
response while 2-8µm particles induce IL-4 secretion and favour a Th2 type response [52]. From an 144 
immunological context, this may be linked to the differential uptake of these nanomaterials as 145 
smaller nanoparticles may differentially accumulate in macrophages compared to larger 146 
nanoparticles [51, 53].  147 
Unwanted immune stimulation is a hurdle for the development of some nanomaterials, but it does 148 
also present an opportunity for the formulation of certain therapeutics, in particular, antigens to be 149 
utilised in vaccines. The use of nanoparticles as adjuvants has been reported by numerous studies. 150 
Poly(methyl methacrylate) (PMMA) nanoparticles have been shown to induce long-lasting antibody 151 
titres in HIV-2 whole virus vaccine in mice, and the antibody response was 100-fold higher than that 152 
of standard adjuvant [54]. Similarly, the levels of specific antibodies produced in the immunisation of 153 
animals with colloidal gold conjugated antigens were higher than that generated by classical 154 
adjuvants while the amount of antigen required to achieve this response was an order of magnitude 155 
lower than for immunisation with a standard adjuvant [55]. The reasons for this may be due to 156 
greater accumulation of the antigen in cells such as dendritic cells allowing greater presentation of 157 
the therapeutic antigen to the immune system.  158 
Concerning the formulation of vaccines, the generation of inflammation is desirable when 159 
nanoparticles are targeted to dendritic cells (DCs). DCs have the ability to induce and modulate the 160 
immune response. DCs play a key role in the activation of T cells and as such are a principal target for 161 
most vaccines. Utilization of “danger signals” in vaccine design (DC activating non-host signals) 162 
combined with specific antigen to induce the desired immune response type is a common approach 163 
[56]. As mentioned earlier, nanoparticle size can govern their immunostimulatory profile with 164 
plasmacytoid DCs (pDCs) showing preferential uptake of nanoparticles <200nm, resulting in the 165 
production of IFNα while phagocytosis by monocytic DCs (mDCs) of 500-1000nm particles induced 166 
TNFα [57]. Similarly, Gadolinium containing nanoparticles have been reported to possess antitumour 167 
activity resulting from their ability to induce the maturation of immature DCs [39]. Stimulation of 168 
DCs by TMC-TPP nanoparticles has been shown to induce differentiation of T cells to inflammatory 169 
TH17 [58]. As an alternative proinflammatory pathway to TH1- and TH2-type responses the IL-17 170 
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mediated cascade offers a further mechanism for enhanced effect as an adjuvant. The opposite 171 
effect was observed following DC stimulation by PLGA nanoparticles where not only was TH17 172 
differentiation inhibited but also differentiation of naïve CD4+ T cells to FoxP3+ T cells (Treg cells) was 173 
observed. The anti-inflammatory role which Treg cells play in self-antigen tolerance, inhibition of T 174 
cell response, cytokine release, as well as NK and CD4+ cell activity would not be favourable for a 175 
vaccine-based application.  Determination of the favourable characteristics of nanoparticles that are 176 
correlated with the desired effect is vital to the development of future nanomaterials.  177 
The application of knowledge regarding the biodistribution and accumulation of nanomaterials in 178 
vivo [59] is highly important when interpreting immunogenicity not only regarding use as adjuvants 179 
but for general safety. Passive and active accumulation of nanoparticles in multiple sites increase the 180 
concern of off-target toxicity. The relationship between administration route and biodistribution of 181 
nanoparticles is intrinsically linked, and to date, there exists no thorough evaluation of route of 182 
administration, and how it relates to cytotoxicity following tissue accumulation.  183 
Suppression of the immune system by nanoparticles 184 
Immunosuppression can be the result of numerous biological effects both directly and indirectly 185 
resulting from the systemic presence of nanomaterials. Identification of immunosuppressive effects 186 
of nanoparticles is complicated by the fact that these effects may be subtle and not identified until 187 
long-term exposure to nanoparticles. Thorough, long-term study is required for the evaluation of 188 
immune suppression and careful consideration of the factors involved is required. Unintended 189 
immune suppression is an undesirable outcome in areas where patients may already be 190 
immunocompromised such as in cancer and HIV infection. Identification of undesirable 191 
immunosuppressive properties of engineered nanomaterials may be an important component of 192 
their preclinical evaluation. The current knowledge of immunosuppression by nanoparticles has 193 
been recently reviewed [60, 61] but some key examples are elaborated in this section. 194 
The possible mechanisms by which immunosuppression may occur can be linked to direct anti-195 
inflammatory activity of nanoparticles (silver nanoparticles [62]), nanoparticles with antioxidant 196 
activity (cerium oxide nanocrystals [63]), those with anti-cytokine activity (citrate-stabilized gold 197 
nanoparticles [64, 65]), inhibitors of cell-mediated immunity (iron oxide nanoparticles [66]), those 198 
that interfere with normal antigen response (multi-walled carbon nanotubes [67]), inducers of 199 
myelosuppression (doxorubicin bound to polyisobutyl [68]), and those cytotoxic to immune cells 200 
(zinc oxide [69]). The range of nanomaterials associated with these outcomes is quite broad, some of 201 
which mediate their effects via multiple mechanisms [60]. 202 
The generation of oxidative stress following accumulation in cells is the primary mode of toxicity for 203 
some nanomaterials as demonstrated in Figure 1. Generation of reactive oxygen species is linked 204 
with activation of the NLRP3 inflammasome [70] which in turn triggers release of proinflammatory 205 
cytokines IL-1β and IL-18 [71], leading to immune stimulation. Certain nanoparticles, including 206 
cerium oxide and gold nanoparticles [72, 73], have been found to have antioxidant activity due to 207 
their ability to quench free radicals.  208 
Nanoparticles such as citrate-stabilised gold have demonstrated anti-cytokine activity by 209 
sequestering extracellular IL-1β [65] thereby inhibiting responses initiated by IL-1β in certain cell 210 
lines. Additionally, interference with TLR9 translocation, via binding of the signalling regulator high-211 
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mobility group box-1 (HMGB1) [64], therefore diminishing the effect of TNFα generated by an 212 
immune stimulant (CpG-ODN). The binding potential of gold nanoparticles is a commonality that 213 
underpins the proposed mechanisms.  214 
Fullerenes [74] and carbon nanotubes [67] have been strongly associated with immunosuppression 215 
by interfering with the normal response of immune cells to antigens while many dendrimers are 216 
being studied to exploit their immunosuppressive qualities [75]. Large amine-and hydroxyl-217 
terminated dendrimers were shown to be able to inhibit inflammation via inhibition of 218 
cyclooxygenase (COX1 and COX2) in a concentration-dependent manner [76]. 219 
API involvement in nano-immunomodulation 220 
While inadvertent immunosuppression could result in catastrophic consequences, especially in 221 
diseased states with associated immunocompromisation, it may be desirable when utilized in the 222 
treatment of inflammatory disorders and autoimmune disease. The clinical potential to improve 223 
transplant acceptance by the prevention of allergic responses would be invaluable, and current 224 
progress shows great promise by utilizing nanocarriers for the delivery of immunomodulating agents 225 
such as rapamycin [77] or donor antigens for the induction of transplant tolerance utilizing 226 
vaccine/adjuvant principals [77, 78]. 227 
Controlled delivery of active pharmaceutical ingredients (APIs) to target sites using nanocarriers is an 228 
ongoing challenge. Underpinning this is the need to assess potential and effects of the accumulation 229 
of APIs in off-target tissues or immune cells. Polymeric and liposomal carriers are well known to have 230 
a higher accumulation in the lymphatic system [79] wherein their potential to interact with 231 
lymphocytes in a non-beneficial manner poses cause for concern. Lopinavir, a protease inhibitor 232 
used in the treatment of HIV the nanoformulation of which is currently in development [80] has 233 
been shown to induce cytokine secretion from various immune cells [81], and Rapamune [82] a 234 
nanoformulation of rapamycin used as an immunosuppressant, although possessing antipodal 235 
immunological effects are both pertinent examples of APIs whose impacts need to be assessed 236 
separately to their carrier system. Following accumulation or degradation of either API or carrier, 237 
any associated immunomodulatory effects could become apparent. Immunostimulatory or 238 
immunosuppressive properties of the API potentially enhance, or mask those of the carrier system 239 
and vice versa. Whether they are by design or unintentional, such effects need to be fully accounted 240 
for.  241 
 242 
Interaction of nanoparticles with components of the blood 243 
Many nanoparticles have been shown to influence a number of haematological components and 244 
processes [83]. In their normal homeostatic role platelets facilitate coagulation and are involved in 245 
the thrombogenic process to stop bleeding [84]. Platelet activation and thrombus formation have 246 
been found to occur in response to nanomaterials in the systemic circulation [85]. Platelet 247 
aggregation following the activation of glycoprotein integrin receptor GPIIb/IIIa has been observed 248 
for both single walled carbon nanotubes (SWCT) and multi-walled carbon nanotubes (MWCNT) in a 249 
particle size-dependant manner [85]. Platelet activation has also been strongly associated with 250 
GPIIb/IIIa activation by silver ions released from silver nanoparticles [86, 87] and increased 251 
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intracellular calcium ion concentration resulting from silica nanoparticles [88]. The interaction of 252 
charged polystyrene latex nanoparticles has been found to cause physical bridging of platelets in a 253 
GPIIb/IIIa independent manner [89]. 254 
The properties of size, charge, hydrophobicity, and the presence of certain surface groups can 255 
determine thrombogenicity of nanoparticles resulting from altering prothrombin times and activated 256 
partial thromboplastin times, as well as the mechanism by which coagulation is induced [83]. Anionic 257 
polystyrene latex nanoparticles caused platelet aggregation via upregulation of adhesion receptors 258 
while their cationic counterparts initiated platelet aggregation following destabilization of cell 259 
membrane integrity [90]. Amine-functionalized nanoparticles reduced thrombin production via 260 
depletion of factors VII and IX in a size dependent manner [91]. It has been shown that these 261 
characteristics hold greater influence over thrombogenicity than does the basic composition of a 262 
given material [83]. Cationic, but not neutral or anionic, PAMAM dendrimers cause platelet 263 
aggregation [92, 93]. The size-dependence of polystyrene nanoparticles to cause coagulation has 264 
been suggested because 220nm but not 24nm particles exhibited this effect [91]. 265 
 266 
Links between immunological and haematological systems 267 
Immunological and haematological systems do not function in isolation and have evolved to work 268 
cooperatively to both detect infection and ensure resolution of the response. There are a number of 269 
examples of how nanoparticles interact with one system, which in turn activates the other. 270 
Leukocyte procoagulant activity 271 
Leukocytes play key roles in the regulation of thrombin formation [94] having an influence over 272 
inflammation, wound healing and atherosclerosis. Monocytes and neutrophils [95] are recruited by 273 
activated platelets at sites of thrombogenesis. This is achieved via recognition of P-selectin on the 274 
activated platelet by leukocyte P-selectin glycoprotein ligand (PSGL)-1 resulting in conformation 275 
changes in β2 integrins [96] leading to potent procoagulant activity. Induction of tissue factor 276 
synthesis, the presence of which is necessary for the production of thrombin, leads to thrombus 277 
formation [97]. 278 
Contamination of materials can have a great effect on the pro-coagulant activity of leukocytes. It has 279 
been shown that the presence of endotoxin confers leukocytes with considerable procoagulant 280 
activity [98]. Contamination of nanomaterials by endotoxin may cause false positives in many 281 
immunological assays and it has been demonstrated that cationic PAMAM dendrimers have been 282 
shown to enhance the procoagulant activity induced by endotoxin [99, 100]. 283 
Complement activation 284 
The complement system is a vital component of the innate immune system with functions involved 285 
in homeostasis, pathogen recognition, and determining the appropriate immune response be it 286 
innate or adaptive [101]. Nanoparticles have been shown to activate the complement system 287 
following intravenous injection [102]. It is a multicomponent system made up of over 30 membrane-288 
associated and soluble proteins [103]. Complement activation leads to sequential reactions resulting 289 
in the formation of C3a and C5a anaphylatoxins which exert multiple inflammatory responses which 290 
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include the recruitment of phagocytes [103]. Numerous studies have pointed towards complement 291 
activation being a contributing factor in the development of hypersensitivity and anaphylaxis as a 292 
response to the systemic presence of nanoparticles [6, 104, 105]. Hypersensitivity reactions have 293 
been reported for the liposomal formulation Doxil™ [106] there is evidence that this is mediated by 294 
complement activation [105]. It has been described that polymeric nanoparticles consisting of PEG-295 
PL (block copolymers of poloxamer and poloxamine) can activate complement exclusively via the 296 
lectin pathway [107]. This mechanism is normally reserved for the recognition of repeating and 297 
charged motifs of certain polysaccharides [108]. 298 
Platelet activation and immune stimulation 299 
The link between platelet activation and immune stimulation is multifactorial and double-edged. 300 
While thrombogenesis can influence immune stimulation, along with various thrombogenic factors 301 
being able to inhibit or augment immune responses, the opposite is also true where immune 302 
stimulation increases thrombogenic potential. Proinflammatory cytokines and endotoxin induce 303 
tissue factor production on leukocytes which in turn initiates extrinsic coagulation via thrombin (FIIa) 304 
generation [109]. Complement activation leads to enrichment of plasma membrane surfaces with 305 
negatively charged phospholipids which have been shown to amplify coagulation [110]. 306 
Thrombogenic function is just one of the numerous activities which platelets can play within 307 
homeostasis. The involvement of platelets within immune stimulation has gained recognition in 308 
recent years [111, 112]. Platelets carry numerous receptors including TLRs and express 309 
immunomodulatory molecules and cytokines [113]. An example of how nanoparticles may cause 310 
immune stimulation via platelets has been demonstrated previously with multi-walled nanotubes 311 
(MWNT). MWNT were shown to induce the release of platelet membrane microparticles capable of 312 
stimulating other immune cells [114].  Further studies are warranted on the interaction of platelets 313 
and immune cells with respect to nanoparticle effects on both cell types. 314 
Haemolytic potential 315 
The mechanisms of nanoparticle-mediated haemolysis are not fully understood. Haemolysis is the 316 
result of damage to red blood cells and may be used as a measure of cell viability in response to 317 
contact with materials in addition to possibly leading to anaemia [115]. Many studies currently exist 318 
which describe the haemolytic potential of various nanomaterials but only some suggestions exist 319 
concerning their mode of action [104] primarily membrane disruption via interactions with red blood 320 
cell membrane phosphatidylcholine [116, 117]. Charge has been shown to strongly influence 321 
whether nanoparticles cause haemolysis. This process has been related to the disruption of cell 322 
membranes via pore formation following the integration of charged nanoparticles into existing 323 
membrane defects [118]. The potential for nanoparticles to become ionised [119], surface groups 324 
[116, 117], and cationic charge seem to be parameters likely to have an effect. Materials which 325 
exhibit this trend include silica nanoparticles [120, 121] as well as numerous others via the presence 326 
of unprotected amines on the nanoparticle surface such as PAMAM [122], carbosilane [123], 327 
polypropylene imine [124], and polylysine [125] dendrimers, which have been associated with 328 
erythrocyte damage in a dose dependent manner. The haemolytic potential of silver nanoparticles 329 
has been well described in numerous sources [86, 119, 126]. It has been demonstrated that with 330 
increasing hydrophilicity the haemolytic potential increases [127]. The presence of a protein corona 331 
has been shown to have a protective effect, and the haemolytic potential of gold nanoparticles 332 
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featuring both hydrophobic and hydrophilic surface functionalization was reduced [127]. This effect 333 
has also been described by Tenzer et al. wherein the presence of protein corona on silica 334 
nanoparticles negated their haemolytic activity as well as a reduced level of thrombocyte activation 335 
compared to pristine nanoparticles [31]. 336 
 337 
Challenges in assessing the biocompatibility of novel, engineered, nanoparticles 338 
Contamination 339 
The potential for nanomaterial contamination is intrinsically linked to the associated manufacturing 340 
process. Bacterial endotoxin is a contaminant which elicits a strong immune response upon 341 
exposure [128]. Endotoxin is a component of Gram-negative bacterial cell walls and can contaminate 342 
nanomaterials during the manufacturing process or in handling. It has been shown that endotoxin 343 
can exacerbate inflammatory responses to nanoparticles [129-132]. As a result of the potent 344 
proinflammatory activity the presence of endotoxin in nanomedicines whose administration to 345 
individuals in an already diseased state leads to the question of how this, in combination with 346 
potential nanoparticle associated immunomodulation, may affect an already compromised immune 347 
system.   348 
The formulation of nanomedicines can represent complicated, multistep processes often involving 349 
the use of volatile chemicals and reagents. These volatile agents must be removed to prevent 350 
toxicity being generated by carry-over from contaminants within the formulation process [133]. The 351 
cytotoxic analysis of a preparation of gold nanorods both pre- and post-purification has 352 
demonstrated the stark contrast which can be the result of residual manufacturing components 353 
[134]. This observation has also been described by some sources where the toxicological potential of 354 
carbon nanotubes has been assessed [135, 136]. The production of carbon nanotubes requires 355 
catalysis by transition metals [137]. Most frequently these are iron, nickel, and copper. As free ions, 356 
these metals have been shown to induce oxidative stress via the production of reactive oxygen 357 
species (Figure 1) [138, 139]. Chemical contamination of this type has been detected in commercially 358 
available preparations of carbon nanotubes where, following purification, the material was no 359 
longer deemed toxic [140].  360 
Nanoparticle interference with assays 361 
A number of in vitro assays have been adopted for use with nanomaterials [141]. Their translation to 362 
use in nanotoxicology is mainly due to their track record of versatility, simplicity, and reproducibility. 363 
As has become apparent in recent years; the appropriateness to apply these methodologies with 364 
little consideration to how novel materials may lead to spurious assay outcomes [142]. Determining 365 
the appropriateness of assays for this end is complicated by the intrinsic complexity of nanoparticles. 366 
As such, suitable inhibition/enhancement controls (IEC) should be included in this analysis when 367 
possible.  368 
Adsorption of protein to the surface of nanoparticles reduces the concentration of free protein 369 
available for quantification. The polarity of nanoparticles can enhance or reduce their potential for 370 
binding proteins from a matrix. This is particularly evident by the reduction in measurable IL-8 due to 371 
adsorption to a titanium dioxide preparation [142]. Similarly, TLR9 and IL-1β binding to citrate-372 
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stabilized gold nanoparticles has been documented [64, 65]. The ability of nanoparticles to interact 373 
with, and inactivate enzymes is a consideration which reaches beyond the potential in vitro and in 374 
vivo effects. Numerous methods for testing the toxicity of nanomaterials rely on enzymatic function. 375 
The potential for interaction dictates that further considerations be made so as not to generate data 376 
which may not be representative of the material but merely an artefact of experimental interference 377 
[143]. Few assays have been implicated with this form of interference to date. One that has been 378 
brought to light is the LDH assay. Inactivation of lactate dehydrogenase as a result of adsorption to 379 
nanoparticle surfaces has been presented as a mechanism by which the LDH assay can produce 380 
results which are not an accurate representation of nanoparticle action [142, 143].  381 
Studying the haemotoxic effects of nanomaterials lends the opportunity for a number of 382 
methodological issues relating to the basic properties of nanoparticles under investigation. The 383 
turbidity of nanoparticle preparations is known to interfere with platelet aggregometry, the principal 384 
of which relies on the optical assessment of the decrease in turbidity due to platelet aggregation. A 385 
potential solution for this is to utilize alternative measurement methods such as flow cytometry. 386 
Systems utilising magnets, such as those used for measuring platelet activation, have the potential 387 
to be incompatible with magnetic nanoparticles. When subjected to the magnetic field a region of 388 
higher concentration may establish, the effect of which may skew any observations and not be 389 
representative of a uniform distribution.  390 
Proliferation is commonly evaluated using the MTT assay, but there are numerous mechanisms by 391 
which this can be incompatible with nanomaterials. A potential issue with the use of this assay is 392 
that it relies on the metabolic conversion of the MTT compound. Materials which promote/alter 393 
mitochondrial biogenesis cause artificially high signal which could be mistaken as pro-proliferative 394 
[144]. Differences in rates of tetrazolium production is reflective of the metabolic state of the cells 395 
[145, 146]. It is known that activated lymphocytes are more metabolically active than non-activated, 396 
which may reflect altered metabolism rather than proliferation [147]. Nanoparticles affecting 397 
metabolism and proliferation would be difficult to discern so the use of further methods such as 398 
[3H]thymidine incorporation and CFSE should be utilised. Quantification of cytokines as a marker of 399 
proliferation can also be problematic as the reduction may be the result of cell death.  400 
The issues described here hold equal validity not only for toxicity assays but for immunotoxicity as 401 
the reagents employ similar strategies for generation of a measurable result i.e. absorbance, 402 
fluorescence. As such, the potential for nanoparticle-based assay interference must be considered 403 
throughout assay development and data interpretation.  404 
Nanoparticle physicochemical characteristics in biological matrices 405 
In order to determine structure-activity relationships and define meaningful trends, it is necessary to 406 
accurately measure physicochemical characteristics. The application of nanomaterials under 407 
biological conditions, both in vitro and in vivo, require in-depth knowledge of their physicochemical 408 
properties in relevant matrices. Due to the increasing complexity of biological matrices, it is not 409 
sufficient to assume that characteristics determined under minimal conditions (i.e. under vacuum, or 410 
in water) are still valid in the rational design and development for given purposes. The size, charge, 411 
surface chemistry, stability, and a host of other properties can be directly and dramatically altered 412 
by the medium in which the nanoparticles are suspended, all of which may affect how the materials 413 
interact with biological processes [148, 149]. 414 
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Not only is it important to produce accurate and appropriate determinations of the physicochemical 415 
characteristics of nanomaterials, but it must be appreciated that the production of such materials is 416 
often a complex multistep process. Changes in particle size and/or charge can affect particle 417 
biodistribution, immunological impact and broader aspects of safety for nanoparticles made of the 418 
same material [93, 100]. While polydispersity within and between preparations must be expected, 419 
this batch-to-batch variability must be strictly monitored and accounted for to minimize 420 
downstream issues.  421 
The issue of determining biologically meaningful in vitro assays which can inform downstream in vivo 422 
studies is further complicated by the choice of appropriate cellular models and endpoints. A recent 423 
review by Dobrovolskaia [150] has examined these considerations in detail, as such will not be 424 
repeated here. Linked with this are need to choose relevant and efficacious controls as well as 425 
determine any interaction between the nanomaterial and assay itself. To exemplify this issue, it was 426 
earlier mentioned that numerous cytotoxicity assays are prone to nanoparticle-related interference. 427 
Without detailing the choice of cell line or endpoint the choice of controls and assay interaction 428 
potential shall be discussed. The cytotoxic compound of choice must be sufficiently potent within 429 
the given cell line to generate toxicity but would ideally have a mode of action similar to that which 430 
would be expected from a nanomaterial. While this is desirable, tetrazolium salts such as MTS/MTT 431 
which detect the REDOX potential of cells would not be necessarily compatible with ROS generators 432 
such as dicumarol which can lead to overestimation of cellular viability and proliferation [151]. 433 
Similarly, compounds which affect cell membrane integrity should be used with care in the LDH 434 
assay, especially when comparing results of different cytotoxicity assays. Cell-free preparations of 435 
assays can be considered vital as a means to not only generate a baseline but also to observe any 436 
concentration dependent interactions that may occur. This can be invaluable in fluorogenic assays 437 
such as DCF where a threshold for interference may exist [152]. As mentioned earlier, the inclusion 438 
of inhibition/enhancement controls can assist in determining whether observations are a result of 439 
cellular interactions with nanomaterials or solely due to the presence of the nanomaterial. This is 440 
becoming routine in limulus amoebocyte lysate (LAL)-based assays for measuring endotoxin in which 441 
a nanomaterial sample is spiked with a known amount of endotoxin and assessed for enhanced or 442 
diminished recovery [153]. The underlying principal is translatable to a host of assays in which 443 
inducers or inhibitors of the desired effect can be introduced in addition to nanomaterials. Although 444 
logical, these considerations are widely overlooked potentially resulting in misleading conclusions 445 
being drawn.   446 
 447 
Considerations for specific patient populations 448 
Research efforts examining the biocompatibility of nanomaterials primarily use blood, as well as 449 
immune cells, from healthy volunteers to assess potential interactions. However, the intended 450 
populations often have differential immunological profiles compared to healthy volunteers.  It is, 451 
therefore, vital that these aspects be considered when testing novel engineered nanomaterials.  452 
The broad concepts of immunological frailty and how they relate to potential interactions with 453 
nanomaterials has been described [154] and highlights the relative lack of experimental evidence in 454 
such populations compared to investigations in healthy volunteer cells and tissues. There is evidence 455 
to suggest that the genetic background of the test organism can influence the outcome of 456 
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biocompatibility testing. Gustafsson et al. [155], showed that the response to titanium dioxide 457 
nanoparticles in rats was strain-specific, indicating that genetics plays a role in the response to 458 
nanomaterials. Existing data on the effects of nanoparticles in animal models reflecting 459 
immunological frailty, dysregulated immunity and immune-compromised states show that 460 
nanoparticles can have greater, or an additive, toxicological effect to that resulting from the 461 
diseased state [156]. However, how closely animal models can reflect the situation in humans with 462 
respect to disease states is an ongoing issue surrounding many fields of research, and it seems likely 463 
that obtaining ex vivo samples from patients with specific conditions may complement other pre-464 
clinical evaluations, prior to phase I trials. 465 
As one would expect, potential side effects and immune interactions by nanomaterials may be 466 
further influenced by dysregulation of the immune system as a result of the diseased state. HIV is a 467 
pertinent example of this, wherein the disease is underpinned by complex multifactorial 468 
immunomodulation, and treatment paradigms are currently being investigated for improvement via 469 
the application of nanoformulation [157]. 470 
There exist several parallels between the immunological effects of nanomaterials and those of the 471 
diseased state. These effects include some generated by chronic inflammation such as rheumatoid 472 
arthritis, cancer, and even hepatitis and HIV.  473 
As mentioned previously, the activation of TH17 type response by TMC-TPP nanoparticles leads to 474 
the generation of IL-17 [58]. The generation of this particular proinflammatory factor is of interest in 475 
the pathogenesis of rheumatoid arthritis, as its production in the synovial tissue has been shown to 476 
promote destructive collagen arthritis in an IL-1 independent manner in murine models [158], and 477 
act synergistically with IL-1 and TNFα [159] .  478 
The pathogenesis of cancer is intrinsically linked to a multitude of cytokines generated by the innate 479 
and adaptive immune systems including IL-1, IL-6, IL-12, IFNγ, TNFα [160] all of which have been 480 
shown to be associated with the interactions of various nanoparticles including silver (IL-1) [161], 481 
MWCNT (IL-6) [162], and zinc oxide (IL-12, IFNγ, TNFα) [69]. As a platform for immunotherapy 482 
nanoparticles are being studied due to their known induction of various immunostimulatory 483 
cytokines which are proposed to exacerbate, and illicit, a greater immune response against 484 
cancerous cells.  485 
Mechanisms proposed to result in apoptosis in HCV and HIV-infected cells include loss of cell 486 
membrane integrity, mitochondrial dysfunction and generation of ROS [163]. Silica [164] and 487 
titanium dioxide [165] nanoparticles have been shown to alter cell membrane integrity in a charge- 488 
and concentration-dependent manner. Oxidative stress and the generation of reactive oxygen 489 
species is directly relatable to mitochondrial dysfunction (Figure 1) [166]. A large number of 490 
nanomaterials have implicated with having a similar effect [167]. HIV has been shown to interfere 491 
with the autophagic process via inhibition in dendritic cells, and induction in macrophages [168], 492 
while HCV has shown to increase levels of autophagy in infected cells [169]. Inhibition [170] or 493 
induction [171] of autophagy by nanomaterials (Figure 1) is also a commonality to the actions of HIV 494 
and HCV. Therefore, it seems likely that certain material compositions should not be progressed for 495 
certain applications. 496 
14 
 
Immunocompromised individuals can be defined as having a substantially weakened immune 497 
system, and this was originally thought to be the case in HIV infection. However, it is now known 498 
that the situation is not clear cut since a patients’ immunological profile varies with the type of viral 499 
populations infecting them and their response to antiretroviral therapy [172]. Infection with HIV 500 
leads to a decline in CD4+ T cells, but treatment with antiretrovirals may produce resurgence in the 501 
number of these cells. However, it has been shown that although the number of CD4 T cells 502 
increases their functional capacity is diminished in chronic infection. This has been demonstrated by 503 
the increased expression of the receptor programmed death 1 (PD-1), a negative regulator of 504 
activated T-cells [173]. Cells expressing high levels of PD-1 were shown to be functionally exhausted 505 
compared to uninfected cells suggesting HIV+ patients are immunocompromised [174]. However, 506 
the reasons for this exhaustion of the immune system are unclear, and several hypotheses have 507 
been proposed [175]. An interesting hypothesis for the ongoing inflammation seen in HIV, which 508 
may be linked to T cell exhaustion, is the discovery that HIV itself can induce an inflammatory form 509 
of programmed cell death termed pyroptosis. Dotish et al. showed that HIV can directly induce 510 
pyroptosis in CD4 T cells via inflammasome activation and that this process could be blocked by 511 
inhibiting caspase-1 [176]. Interestingly, nanoparticles have been shown to interact with 512 
inflammasomes, NLRP3 in particular (Figure 1) [177] and carbon nanoparticles have been shown to 513 
induce pyroptosis [178].  This is an important consideration for the application of nanoparticles 514 
either in the treatment of HIV infection or when nanoparticles may be applied in HIV+ patients for 515 
concomitant health issues, e.g. raised cholesterol or infections. As a condition where chronic dosing 516 
is a reality which cannot be overlooked, the long term effects of any nanoformulation must be 517 
considered and is something we are investigating with interest.  518 
Effects such as these may be tolerable in a healthy model but be potentially incompatible with the 519 
diseased state. It is also possible for the opposite to be true, where the observable effect is 520 
unacceptable under healthy conditions, whereas its effect on the diseased state may not be as 521 
pronounced and within a range where the potential benefits outweigh the negative outcomes. As is 522 
demonstrated in Figure 2 the primary considerations of the nanomaterial itself, the immune system 523 
to which it will be introduced, and the disease on which it will act are not mutually exclusive. The 524 
intersections of biocompatibility and treatment response are those which weigh heavily in the 525 
development of nanomedicines. Often overlooked is the immune response relating the disease to 526 
the immune state, and also how the nanomaterial has influence over these. To be able to create a 527 
truly appropriate model for the design of nanomedicines, a holistic approach such as this must be 528 







Figure 2 - Key challenges in compatibility of nanoparticles as nanomedicines. Considerations 534 
involved in the design, analysis, and application of nanomaterial for the treatment of disease linking 535 
the material specific, immune state, and particular disease. A more holistic approach incorporating 536 
investigation of immunological status and genetic variability in genes encoding immune signalling 537 
proteins will allow a more holistic approach to the biocompatibility testing of novel engineered 538 
nanomaterials. Acronyms used; PCC – physicochemical characteristics, HIV – human 539 
immunodeficiency virus, JSLE – juvenile systemic lupus erythematosus. 540 
 541 
US and EU efforts to promote the harmonization of nanoparticle testing  542 
To truly determine relationships between nanoparticle characteristics, the necessity to apply a more 543 
standardised approach to assays has become apparent in order to correctly assess how 544 
nanoparticles interact with biological systems. Many researchers involved in the development of 545 
nanomaterials use well-defined assays to assess biocompatibility e.g. investigation of cytotoxicity by 546 
using MTT assays. However, there are reports of contradictory test results from cell-based assays 547 
[179, 180]. Unexpected variability can arise in such assays by differences in media composition, 548 
passage time of cell lines and the source of the serum used in routine cell culture media. The 549 
National Cancer Institute’s Nanotechnology Characterisation Laboratory (NCI-NCL) 550 
(http://ncl.cancer.gov/) has been at the forefront of promoting harmonisation of assays to 551 
determine nanoparticle interactions with biological systems and offers standardised methodologies 552 
for its assessment. Given the increasing development of nanomaterials across Europe, a need has 553 
been identified to begin to regulate the preclinical evaluation of novel engineered nanomaterials as 554 
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well as provide a platform for the translation of these materials into clinical studies. The recently 555 
established European Nanomedicine Characterization Laboratory (EU-NCL) (http://www.euncl.eu/) 556 
shares the same ethos as the NCI-NCL in the provision of a standardised characterisation of 557 
nanomedicines to aid in their translation to the clinic and facilitate nanomedicine development. 558 
Currently, researchers and developers in Europe have to gather preclinical data from a multitude of 559 
non-integrated providers which may result in interlaboratory variability and, therefore, conflicting 560 
results. A major ambition of the EU-NCL is to tackle that obstacle by providing an open-access EU-561 
wide characterisation infrastructure and maintain Europe as internationally competitive in 562 
nanomedicine development. EU-NCL offers a unique integrated solution ensuring access to high-563 
quality data, experience, and facilities throughout Europe for a large range of medical applications. 564 
EU-NCL is a multi-centre infrastructure which is intended to overcome current fragmentation and to 565 
improve quality and efficiency of translation by drawing on expertise across Europe. The 566 
involvement of multiple analytical centres guarantees direct access to different domains in the 567 
nanomedicine communities and other stakeholders while maintaining the bandwidth to engage with 568 
Europe’s most promising candidates. It is envisaged that using this integrated approach, EU-NCL will 569 
also be able to determine critical nanoparticle characteristics that relate to biological effects, 570 
without compromising confidentiality with developers. As such, this will enable researchers to 571 
access anonymised information to inform future rational design of nanomaterials. 572 
 573 
Conclusions and future perspectives  574 
The development, and implementation, of nanomaterials for a variety of clinical applications is 575 
increasing as their utility in improving healthcare is demonstrated. However, consideration must be 576 
given to appropriate pre-clinical testing to fully translate these materials into clinical use.  577 
Numerous conclusions can be drawn from existing research, among which are perspectives on how 578 
pre-clinical testing can be improved from its current state. As mentioned here thorough 579 
physicochemical characterisation in biologically relevant matrices is vital, similarly assessing the 580 
contamination state of products. These need to be supported by biologically meaningful in vitro 581 
assays which can inform further in vivo studies. Linked with this are need to choose relevant and 582 
efficacious controls as well as determine any interaction between the nanomaterial and assay itself. 583 
Greater insight into the effect of nanoparticles on the diseased state would benefit from testing in 584 
relevant patient samples. Finally, the nanomaterials should be considered in the final format for 585 
which they have been developed. Not only will this aid in determining if the nanoparticle is fit for 586 
purpose, but also how its application may affect patient populations in terms of nanomedicine. 587 
It is hoped that with greater integration and cooperation of various research efforts the 588 








 Nanoformulation provides a platform which allows improvement over existing therapeutic 595 
and diagnostic tools. 596 
 Physicochemical characteristics of nanomaterials can be tuned during the manufacturing 597 
process as a means to enhance/reduce physiological effects. 598 
 Challenges in the characterisation of nanoparticles relating to biocompatibility relate to 599 
many factors including different manufacturing processes, and the immune state of the end 600 
user.  601 
Interaction of nanoparticles with components of the immune system 602 
 Various mechanisms, the biological purposes of which under normal circumstances are 603 
homeostatic or relating to clearance of pathogens, are known to be implicated following the 604 
introduction of nanomaterials to biological systems. 605 
 While mechanisms of internalisation of nanomaterials differ as a result of cell type, as well 606 
as physiochemical characteristics i.e. size and charge, downstream effects such as the 607 
generation of reactive oxygen species etc. can be ubiquitous. 608 
 Factors such as protein corona formation, although not well understood, are shown to 609 
modulate biological interactions, uptake, and overall pathophysiology. 610 
 Inflammatory stimulation of the immune system, antibody production against certain 611 
materials are known examples of interactions which may be detrimental to the host.   612 
 Immunosuppressive properties of certain nanomaterials associated with certain 613 
nanomaterials could potentially exacerbate the pathophysiology of immunocompromised 614 
individuals.  615 
 Complexity in these considerations is increased by the presence of active pharmaceutical 616 
ingredients. 617 
Interaction of nanoparticles with components of the blood 618 
 Interactions of nanoparticles with haematological components can lead to modulation of 619 
thrombogenic potential.  620 
 The complexity of these interactions is a function of the physicochemical characteristics of 621 
the nanomaterial as well as the multifactorial nature of the process of thrombogenesis.  622 
Links between immunological and haematological systems 623 
 The cooperation of immunological and haematological systems add complexity to the 624 
evaluation of nanomaterial biocompatibility. 625 
 Leukocyte procoagulant activity is shown as an example where contamination of 626 
nanomaterial preparations can strongly generate a false positive. 627 
 Complement and platelet activation are complex cascades both of which have been shown 628 
to be affected by the presence of various nanoparticles.  629 
 Disruption of membrane integrity leading to haemolysis has been associated with a number 630 
of nanomaterials. The presence of a protein corona modulates this activity.   631 
Challenges in assessing the biocompatibility of novel, engineered, nanoparticles 632 
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 The contamination state of tested materials, both biological and chemical, can skew data by 633 
the generation of false positives. 634 
 The lack of nanoparticle-tailored assays necessitates the use of standard immunological 635 
assays, many of which succumb to interference by intrinsic properties of nanomaterials 636 
which can lead to spurious results. 637 
 The necessity to utilize complementary assessment methodologies which focus on particular 638 
aspects via differential means has been highlighted. 639 
 Physicochemical characterisation in biologically relevant matrices has been highlighted as 640 
providing a more relevant representation of the material coming in contact with cells. 641 
 Suggestions have been provided relating to assay combinations and positive control choices. 642 
Considerations for specific patient populations 643 
 The immunological state of the intended recipient is of primary importance when 644 
considering the application of nanoparticles for nanomedicine.  645 
 The immunological effects of nanoparticles have the potential to exacerbate those 646 
generated by the diseased state.  647 
 Hallmarks of chronic inflammatory conditions display commonality with those generated by 648 
nanomaterials. As such caution must be taken in their use under such conditions.  649 
 Assessment of nanomaterial safety is normally performed in healthy models and while 650 
convenient, does not provide the necessary conditions present in the diseased state. 651 
US and EU efforts to promote the harmonization of nanoparticle testing  652 
 International standardisation efforts for nanoparticle characterisation which can aid 653 
preclinical evaluation of nanomedicines by addressing the aforementioned challenges in 654 
nanomaterial testing 655 
Conclusions and future perspectives  656 
 The need for thorough and biologically relevant preclinical testing is reiterated.  657 
 Consideration of the diseased state in these assessments is of high importance. 658 
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